Earnings summaries and quarterly performance for Nautilus Biotechnology.
Executive leadership at Nautilus Biotechnology.
Sujal Patel
Detailed
Chief Executive Officer
CEO
Anna Mowry
Detailed
Chief Financial Officer
Gwen Weld
Detailed
Chief People Officer
Kentaro Suzuki
Detailed
Chief Marketing Officer
Matthew Murphy
Detailed
General Counsel
Nick Nelson
Detailed
Chief Business Officer
Parag Mallick
Detailed
Chief Scientist
Subra Sankar
Detailed
Senior Vice President, Product Development
Board of directors at Nautilus Biotechnology.
Research analysts who have asked questions during Nautilus Biotechnology earnings calls.
Daniel Brennan
TD Cowen
4 questions for NAUT
Also covers: A, ADPT, AVTR +24 more
Subbu Nambi
Guggenheim Securities
2 questions for NAUT
Also covers: BOLD, BRKR, CARS +16 more
Subhalaxmi Nambi
Guggenheim Securities
2 questions for NAUT
Also covers: AKYA, BRKR, CSTL +15 more
Yuko Oku
Morgan Stanley
2 questions for NAUT
Also covers: ADPT, GH, GRAL +7 more
Elizabeth Koslosky
Goldman Sachs
1 question for NAUT
Also covers: A, DNA
Jason Lai
Citigroup
1 question for NAUT
Also covers: DNA, MYGN, SEER
Matthew Stanton
Jefferies
1 question for NAUT
Also covers: AZTA, BLFS, CDXS +5 more
Matthew Sykes
Goldman Sachs Group Inc.
1 question for NAUT
Also covers: A, ADPT, AVTR +21 more
Recent press releases and 8-K filings for NAUT.
Nautilus Biotechnology Reports Q3 2025 Financial Results and Outlines Commercialization Plans
NAUT
Earnings
Guidance Update
New Projects/Investments
- Nautilus Biotechnology reported a net loss of $13.6 million for Q3 2025, an improvement from $16.4 million in the prior year, with total operating expenses decreasing to $15.5 million from $19.1 million.
- The company ended Q3 2025 with $168.5 million in cash, cash equivalents, and investments, and a cash burn of $11.0 million for the quarter, projecting a cash runway extending through 2027.
- Nautilus plans to launch its early access program in the first half of 2026, starting with the TAU proteoform assay, and anticipates a broad-scale commercial launch by the end of 2026.
- Market research indicates customers view the Nautilus platform as uniquely differentiated and are willing to pay a premium for its capabilities, reinforcing confidence in the commercial opportunity.
- While Q3 2025 was a low point in spending, the company expects operating expenses to increase in future quarters as product and market development activities ramp up towards commercialization.
Oct 28, 2025, 12:30 PM
Nautilus Biotechnology Reports Q3 2025 Financial Results and Commercialization Progress
NAUT
Earnings
Guidance Update
Product Launch
- Nautilus Biotechnology reported a net loss of $13.6 million for Q3 2025, an improvement from $16.4 million in Q3 2024, with total operating expenses decreasing 19% year-over-year to $15.5 million.
- The company ended Q3 2025 with $168.5 million in cash, cash equivalents, and investments, and projects a cash runway extending through 2027.
- Nautilus plans to launch its early access program in the first half of 2026, starting with the Tau proteoform assay, and anticipates a broad-scale commercial launch in late 2026.
- Management expects Q3 2025 to be a low point in spending, with operating expenses anticipated to increase in future quarters as product and market development activities ramp up, and does not expect meaningful services revenue from early access engagements in 2026.
Oct 28, 2025, 12:30 PM
Nautilus Biotechnology Reports Q3 2025 Results and Outlines Commercialization Plans
NAUT
Earnings
Product Launch
New Projects/Investments
- Nautilus Biotechnology reported Q3 2025 operating expenses of $15.5 million, representing a 19% year-over-year decrease, and a net loss of $13.6 million.
- The company ended Q3 2025 with $168.5 million in cash, cash equivalents, and investments, with a cash burn of $11.0 million for the quarter, and projects a cash runway extending through 2027.
- The early access program for the TAU proteoform assay is scheduled to launch in the first half of 2026, with a broad-scale commercial launch anticipated in late 2026.
- Market research involving over 250 decision makers indicated that customers view the Nautilus platform as uniquely differentiated, are willing to pay a premium, and are eager to engage with the technology.
- The company made progress on its TAU proteoform assay, including collaborations with the Allen Institute for Brain Science and the Buck Institute for Research on Aging, and transitioned to a new broad-scale assay configuration.
Oct 28, 2025, 12:30 PM
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
NAUT
Earnings
Guidance Update
Product Launch
- Nautilus Biotechnology reported a net loss of $13.6 million for the third quarter ended September 30, 2025, compared to a net loss of $16.4 million for the corresponding prior year period.
- Operating expenses for Q3 2025 were $15.5 million, a 19% decrease from $19.1 million in the same period last year, driven by operating efficiencies, lower development costs, and reduced salaries and benefits.
- As of September 30, 2025, the company's cash, cash equivalents, and investments totaled $168.5 million.
- The company anticipates launching its early access program with Tau proteoforms in the first half of 2026, with the full commercial launch expected in late 2026.
Oct 28, 2025, 12:00 PM
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
NAUT
Earnings
Guidance Update
New Projects/Investments
- Nautilus Biotechnology reported a net loss of $13.6 million for the third quarter of 2025, an improvement from a net loss of $16.4 million in the prior year period.
- Operating expenses for Q3 2025 decreased by 19% to $15.5 million, down from $19.1 million in the corresponding prior year period, primarily due to operating efficiencies, lower development-related costs, and decreased compensation.
- As of September 30, 2025, the company held $168.5 million in cash, cash equivalents, and investments.
- Nautilus expects to launch its early access program with Tau proteoforms in the first half of 2026, with the full commercial launch of its new broadscale assay format anticipated in late 2026.
Oct 27, 2025, 9:48 PM
Nautilus Biotechnology discusses proteomics platform and market strategy at Q3 Investor Summit
NAUT
Product Launch
New Projects/Investments
Guidance Update
- Nautilus Biotechnology is developing a disruptive iterative mapping platform to address the inefficiencies in drug development by providing a new approach to protein measurement, with a market projected to reach $57 billion by 2030.
- The company plans to launch its platform in late 2026, with the instrument priced at $1 million and consumables designed to generate $1 million in pull-through over time.
- Nautilus reported $180 million in cash on its balance sheet in Q2, anticipating these funds will last through 2027, and has reduced operating expenses by approximately 20% year-over-year.
- Founders maintain significant ownership, holding 32% of the company, indicating strong alignment with shareholder interests.
Sep 16, 2025, 5:00 PM
Quarterly earnings call transcripts for Nautilus Biotechnology.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more